SCHEMBL5659702

SCHEMBL5659702

Cc1cccc(N2C(=O)C(c3cc(C)c(O)c(C)c3)(c3ccc(C)c(C)c3O)c3ccccc32)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.37
POLB P06746 1/20 0.37
RECQL P46063 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SLC6A2 P23975 1/20 0.36
HSP90AA1 P07900 1/20 0.36
MGLL Q99685 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
LMNA P02545 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
MAPT P10636 2/20 0.34
HSD17B10 Q99714 1/20 0.34
CNR1 P21554 2/20 0.32
GPR55 Q9Y2T6 2/20 0.32
GAA P10253 2/20 0.32
PKM P14618 2/20 0.32
MEN1 O00255 1/20 0.32
CASP6 P55212 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5663116 0.93 SLC6A2 (0.36) NPSR1POLBTDP1SLC6A2HSP90AA1
SCHEMBL14457635 0.93 SLC6A2 (0.36) NPSR1POLBTDP1SLC6A2HSP90AA1
SCHEMBL5659537 0.93 SLC6A2 (0.36) NPSR1POLBTDP1SLC6A2HSP90AA1
SCHEMBL5662233 0.90 HSP90AA1 (0.41) NPSR1SLC6A2HSP90AA1MGLLCACNA1B
SCHEMBL5657669 0.89 MAPT (0.39) NPSR1POLBRECQLTDP1MGLL
SCHEMBL5661875 0.88 SLC6A2 (0.37) NPSR1SLC6A2HSP90AA1MGLLCACNA1B
SCHEMBL5659320 0.86 CNR1 (0.37) NPSR1POLBTDP1SLC6A2HSP90AA1
SCHEMBL5659844 0.86 OPRL1 (0.33) NPSR1POLBRECQLTDP1
SCHEMBL5658939 0.84 SLC6A2 (0.36) SLC6A2HSP90AA1MGLLCACNA1BAPBA1
SCHEMBL5660824 0.83 SLC6A2 (0.35) NPSR1POLBSLC6A2HSP90AA1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 NPSR1 246/4885POLB 4753/4885RECQL 3363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.